BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35251586)

  • 1. Is Chinese herbal formula (nourishing Yin therapy) effective and well tolerated as an adjunct medication to hydroxychloroquine in the treatment of primary Sjögren's syndrome? A meta-analysis of randomised controlled trials.
    Li S; Ou R; Liu D; Chen Z; Wei S; Li X; Zhang X; Liu Y; Hou C
    Ther Adv Chronic Dis; 2022; 13():20406223221077966. PubMed ID: 35251586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
    Shao Q; Jin L; Li C; Wang J; Wang M; Wang Q; Wu B
    Explore (NY); 2022; 18(4):416-422. PubMed ID: 34417112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Iguratimod in Treating Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.
    Pu J; Wang X; Riaz F; Zhang T; Gao R; Pan S; Wu Z; Liang Y; Zhuang S; Tang J
    Front Pharmacol; 2021; 12():621208. PubMed ID: 33815105
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of Chinese herbal medicines for nourishing yin, supplementing qi, and activating blood on reproductive endocrine activity and immune functions in patients with primary Sjogren's syndrome.
    Wu GL; Wu NY; Li TY; Fan YS; Yu GY; Lu WW
    Chin J Integr Med; 2015 Oct; 21(10):778-83. PubMed ID: 26525549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Chinese herbal medicine for nourishing yin, supplementing qi, and activating blood on the Th1/Th2 immune balance in peripheral blood in patients with primary Sjogren's syndrome.
    Wu GL; Li TY; Fan YS; Yu GY; Chen J
    Chin J Integr Med; 2013 Sep; 19(9):696-700. PubMed ID: 23975134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effect of Chinese herbal medicine for strengthening qi, nourishing yin, and removing stasis on serum osteopontin and quality of life of patients with primary Sjogren's syndrome.
    Wu GL; Li TY; Fan YS; Yu GY
    Chin J Integr Med; 2011 Sep; 17(9):710-4. PubMed ID: 21910074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of nourishing Yin, strengthening Qi and activating blood decoction on Fas/FasL in salivary glands of NOD mice with Sjogren's syndrome and their mRNA expression].
    Wu GL; Li TY; Lu WW; Yu GY; Fan YS
    Zhongguo Zhong Yao Za Zhi; 2013 Dec; 38(23):4148-51. PubMed ID: 24791507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of iguratimod combined with methylprednisolone for primary Sjögren's syndrome: a meta-analysis and trial sequential analysis.
    Hu G; Yu YF; Yin S; Yang XY; Xu Q; You H
    Eur Rev Med Pharmacol Sci; 2023 Aug; 27(16):7544-7556. PubMed ID: 37667931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.
    van der Heijden EHM; Blokland SLM; Hillen MR; Lopes APP; van Vliet-Moret FM; Rosenberg AJWP; Janssen NG; Welsing PMJ; Iannizzotto V; Tao W; Pandit A; Barone F; Kruize AA; Radstake TRDJ; van Roon JAG
    Lancet Rheumatol; 2020 May; 2(5):e260-e269. PubMed ID: 38273473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effectiveness and Safety of Total Glucosides of Paeony in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.
    Feng Z; Zhang BQ; Zhu YM; Yu BB; Fu L; Zhou LL; Zhou XP; Lu Y
    Front Pharmacol; 2019; 10():550. PubMed ID: 31178729
    [No Abstract]   [Full Text] [Related]  

  • 11. Do the European League Against Rheumatism (EULAR) Sjögren's syndrome outcome measures correlate with impaired quality of life, fatigue, anxiety and depression in primary Sjögren's syndrome?
    Omma A; Tecer D; Kucuksahin O; Sandikci SC; Yildiz F; Erten S
    Arch Med Sci; 2018 Jun; 14(4):830-837. PubMed ID: 30002701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
    Bai W; Yang F; Xu H; Wei W; Li H; Zhang L; Zhao Y; Shi X; Zhang Y; Zeng X; Leng X
    Trials; 2023 Feb; 24(1):112. PubMed ID: 36793118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined use of total glucosides of paeony and hydroxychloroquine in primary Sjögren's syndrome: A systematic review.
    Zhang A; Chen S; Lin R
    Immun Inflamm Dis; 2023 Oct; 11(10):e1044. PubMed ID: 37904705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Go Ask Your Patients! PSS-QoL Reported Perception of Dryness Correlates With Lacrimal and Salivary Flow in Primary Sjögren's Syndrome.
    Lackner A; Bosch P; Zenz S; Horwath-Winter J; Rabensteiner DF; Hermann J; Graninger W; Stradner MH
    Front Med (Lausanne); 2021; 8():660580. PubMed ID: 33937295
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
    Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
    Milic V; Colic J; Cirkovic A; Stanojlovic S; Damjanov N
    PLoS One; 2019; 14(12):e0226498. PubMed ID: 31891590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.
    Jiang W; Zhang L; Zhao Y; He X; Hu C; Liu Y
    Int Ophthalmol; 2020 Nov; 40(11):3059-3065. PubMed ID: 32607949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
    Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
    Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
    Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.